Akebia Therapeutics Inc (NASDAQ: AKBA) on Friday, soared 13.62% from the previous trading day, before settling in for the closing price of $3.01. Within the past 52 weeks, AKBA’s price has moved between $1.07 and $4.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 32.58%. The company achieved an average annual earnings per share of 83.03%. With a float of $254.02 million, this company’s outstanding shares have now reached $263.04 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Akebia Therapeutics Inc is 4.19%, while institutional ownership is 36.59%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.1 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.05) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.03% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Akebia Therapeutics Inc (AKBA) is currently performing well based on its current performance indicators. A quick ratio of 1.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.17, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Looking closely at Akebia Therapeutics Inc (NASDAQ: AKBA), its last 5-days average volume was 6.04 million, which is a jump from its year-to-date volume of 4.2 million. As of the previous 9 days, the stock’s Stochastic %D was 49.73%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 74.26%, which indicates a significant increase from 44.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.67, while its 200-day Moving Average is $2.45.
